



Arzerra® (ofatumumab) – Expanded Indication

- On August 31, 2016, [Genmab announced the FDA approval](#) of [Arzerra \(ofatumumab\)](#) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).
- Arzerra is also indicated for the following indications:
 - In combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate
 - Extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL
 - Treatment of patients with CLL refractory to fludarabine and alemtuzumab
- The expanded indication for Arzerra was approved based on an open-label, two-arm study involving 365 patients with relapsed CLL. Patients were randomized to receive Arzerra in combination with FC or FC alone.
 - The median progression-free survival in the Arzerra arm was 28.9 months vs. 18.8 months with FC alone (HR = 0.67, p = 0.0032).
- Arzerra carries a boxed warning regarding hepatitis B reactivation and progressive multifocal leukoencephalopathy.
- In patients with relapsed CLL, common adverse reactions ($\geq 10\%$) with Arzerra use were infusion reactions, neutropenia, leukopenia, and febrile neutropenia.
- The recommended intravenous dosages and schedules for Arzerra are as follows:
 - In patients with relapsed CLL in combination with FC: 300 mg on day 1 followed 1 week later by 1,000 mg on day 8 (cycle 1), followed by 1,000 mg on day 1 of subsequent 28-day cycles for a maximum of 6 cycles.
 - In previously untreated CLL in combination with chlorambucil: 300 mg on day 1, followed 1 week later by 1,000 mg on day 8 (cycle 1), followed by 1,000 mg on day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles.
 - For single-agent extended treatment in CLL: 300 mg on day 1, followed by 1,000 mg 1 week later on day 8, followed by 1,000 mg 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years.
 - For refractory CLL: 300 mg initial dose on day 1, followed 1 week later by 2,000 mg weekly for 7 doses (infusions 2 through 8), followed 4 weeks later by 2,000 mg every 4 weeks for 4 doses (infusions 9 through 12).
 - In addition, patients should be premedicated with acetaminophen, an antihistamine, and a corticosteroid.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.